Changes
Current field movement is concentrated in state policy, FDA-linked research language, public funding, podcast and media attention, and safety/culture scrutiny. IbogaBase treats this as a source map, not as evidence of treatment availability or clinical proof.
FDA announced that DemeRx NB may begin a closely monitored phase I noribogaine hydrochloride study for alcohol use disorder. This is not drug approval, not a finding of safety or effectiveness, and not patient access guidance.
Oklahoma's bill page shows HB 3834, the Oklahoma Breakthrough Therapy Act for ibogaine clinical trials, approved by the governor on May 12, 2026. It does not make ibogaine FDA-approved and does not erase federal Schedule I constraints.
Texas SB 2308 created a pathway for a selected consortium to conduct ibogaine drug development clinical trials and includes a subchapter that applies only if FDA approves ibogaine for a medical condition. Texas law is not proof of efficacy and does not mean treatment is available outside federal law and research controls.
The Tennessee fiscal note for HB 2075 / SB 2149 describes the Helping Open Pathways to Effective Treatment Act and proposed cohort-based ibogaine drug-development trials. The fiscal note is not clinical evidence and explicitly frames key activity around FDA approval and state/federal constraints.
The source catalog contains a growing podcast/interview directory and a dedicated Listening Library Curator role. Interview statements are not treated as facts until converted into claim records and traced to supporting sources.